Agios Pharmaceuticals Inc. — Sponsor Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

2 Recruiting

5 Completed trials

13 Countries active

3 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase I (Other)

Phase III: 4 Phase II/III: 1 Phase II: 3 Phase I (Other): 1

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Pyruvate kinase deficiency anaemia 2 Myelodysplastic syndrome 1 Sickle cell disease 1 Phenylketonuria 1

Top IMPs

MITAPIVAT 6 AG-946 PHOSPHATE 2 AG-946 1

All trials

9 total

Clinical study to check the Efficacy and Safety of Mitapivat in Patients with Sickle Cell Disease Pending

2024-515202-84-00 Phase II/III 5 countries MITAPIVAT
Evaluation of AG-181 in Subjects 18 to 69 Years of Age With Phenylketonuria Pending

2025-522630-31-00 Phase I (Other) 1 country
A Study of AG-946 in Participants With Anaemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS). Recruiting

2022-500609-42-00 Phase II 8 countries AG-946; AG-946 PHOSPHATE
Study to Evaluate how effective and safe the investigationall product, Mitapivat, is when administred to Pediatric Subjects With Pyruvate Ki… Recruiting

2024-515025-28-00 Phase III 5 countries MITAPIVAT
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease Ended

2024-519746-70-01 Phase II 4 countries AG-946 PHOSPHATE
A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T) Ended

2024-512747-23-00 Phase III 8 countries MITAPIVAT
Study to Evaluate how effective and safe the investigationall product, Mitapivat, is when administred to Pediatric Subjects With Pyruvate Ki… Ended

2024-515024-37-00 Phase III 4 countries MITAPIVAT
A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Non Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE) Ended

2024-512745-16-00 Phase III 7 countries MITAPIVAT
A Clinical Study of Mitapivat in Patients with Sickle Cell Disease and Kidney Disease Ended

2023-510289-28-00 Phase II 2 countries MITAPIVAT

Showing 1–9 of 9 trials

← All sponsors A–Z